In an effort to enhance the medical field in Qatar, G+FLAS, a South Korean company specialising in genome editing, has announced new plans to initiate the development of treatments for genetic diseases in the country.
In collaboration with local talents, a South Korean company has announced plans to start developing treatments for genetic diseases in Qatar, in a move that will strengthen the medical field and enhance the future of genetics in the country.
“Qatar stands out in the Gulf region as a centre for medical excellence, having global educational institutions providing research and development (R&D), training, and education for the future pioneers in the field of medicine and science,” said G+Flags in a statement.
“We at G+FLAS have recognised this and have initiated our goal of establishing a centre in Doha to share our R&D experience in genome editing, CRISPR PLUS technology,” the statement added.
G+FLAS was founded by its CEO Dr Sunghwa Choe in 2014 and has since specialised in CRISPR-Cas genome editing technology and applicational technology development, product development and production of biomedicine and anti-cancer drugs.
“Through the efforts of Mr Dae Ho Kim, G+FLAS Life Sciences will be establishing a base in Qatar to carry forward its R&D, in collaboration with the local medical and agro-related research industry,” said G+FLAS.
Recently, the company received a commendation by the Ministry of SMEs and Startups in South Korea, highlighting the company’s relentless efforts in the medical field.
“Mr Kim comes with over 40 years of Middle East experience and will be heading the locally-established company. Already, patents for Qatar have been filed and several more are in the process. G+FLAS Life Sciences would be established in the country as soon as Mr Kim and his team could visit Qatar,” the statement read.
Mohamed bin Ahmad al-Hayki, Qatar’s ambassador to the Republic of Korea, visited the G+FLAS headquarters in Seoul recently to gain insight on the technology and check the company’s progress in recent years.
“Currently we are working on treatments and vaccines for breast cancer, colorectal cancer, lung cancer, Fabry disease, Covid-19, and herpes zoster, to name a few that are under development,” Kim said.
In addition, G+FLAS’s CEO said that the company is working on a Covid-19 vaccine that is expectedto be ready “by the fall of next year.”
Kim ensured the company “will perform the same level of work as its main company in South Korea” and will “become an essential part of Qatar’s medical and food industry.”